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Down-regulation of Fas gene expression in colon cancer
is not a result of allelic loss or gene rearrangement
LM Butler1, PJ Hewett', WJ Butler2 and PA Cowled1
Departments of 'Surgery and 2Gastroenterology, The University of Adelaide, The Queen Elizabeth Hospital, Woodville, South Australia 5011
Summary Expression of Fas, an apoptosis-inducing receptor, in colonic epithelium is progressively reduced during malignanttransformation.
We have examined the human Fas gene for loss of heterozygosity (LOH) and gross rearrangements in colon tumours and matched normal
mucosa. Polymerase chain reaction (PCR) primers were designed to span a Dral restriction fragment length polymorphic site in the gene.
Heterozygosity was detected in normal DNA samples by PCR amplification of the polymorphic site and restriction enzyme digestion. Thirty-
eight of 88 patients (43%) with colon carcinomas were informative for the assay, and LOH was detected in 6 of the 38 (16%) corresponding
tumours. Tumours from three patients with LOH did not express detectable Fas mRNA, and Fas expression was reduced or absent in 7 of 11
tumours from informative patients without LOH. Southern blotting of tumour DNA samples was used to detect rearrangement of the Fasgene,
but no altered hybridization patterns were observed in 64 tumours analysed. These findings indicate that disruption of the Fas gene is not
primarily responsible for the loss of Fas protein expression reported in colon cancer. We have also shown that loss of Fas gene transcription
is common in these tumours, which may be due to epigenetic gene silencing.
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The size and structure of cell populations are controlled by a
balance between the rates ofcell renewal and death. Physiological
cell death normally occurs as a series of distinct morphological
and biochemical events termed apoptosis (Kerr et al, 1994). In the
colon, apoptosis contributes to the homeostasis of the epithelial
layer ofthe mucosa, which has arapid rate ofcell turnover (Hall et
al, 1994). Apoptosis is also responsible for the removal ofcolono-
cytes with potentially oncogenic DNA damage. Recent studies on
bile acids, which are genotoxic and normally induce apoptosis of
colonocytes, have reported a reduction in the ability of these
agents to induce apoptosis in the normal mucosa of colorectal
cancer patients (Payne et al, 1995; Garewal et al, 1996).
Resistance of colonocytes to apoptosis may allow hyperprolifera-
tion, accumulation ofoncogenic mutations and prevent deletion of
malignant cells by chemotherapeutic agents. Abnormal expression
of the apoptosis-related genes p53 and bcl-2 has been reported in
both benign and malignant colon tumours (Sinicrope et al, 1995;
Scott et al, 1996), however othermolecularmediators ofresistance
to apoptosis remain to be identified.
The Fas antigen (also called APO-1 or CD95) is a cell surface
receptor, homologous to members of the tumour necrosis factor
(TNF) family of transmembrane proteins (Itoh et al, 1991).
Ligation ofFas on the cell surface, by its endogenous ligand or by
agonistic antibodies, triggers rapid apoptosis of the cell (Trauth et
al, 1989; Yonehara et al, 1989). Fas and Fas ligand proteins are
expressed on activated T cells and Fas ligand is expressed on the
surface of cytotoxic T lymphocytes (CTLs). Fas signalling is
required for the apoptotic deletion of autoreactive and activated
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immune cells (Dhein et al, 1995), as well as of virus-infected and
malignant cells by CTLs (Rouvier et al, 1993). Fas signalling has
also been linked to apoptosis outside the lymphoid population,
including the regression of ovarian follicles after ovulation and
maintenance of cellular homeostasis in the liver (Adachi et al,
1995; Hakuno et al, 1996).
The epithelial layer ofthe normal colonic mucosa expresses Fas
protein athigh levels, from the bottoms ofthe crypts to the luminal
surface (Leithauser et al, 1993; Moller et al, 1994). A functional
role for Fas receptors in the colon has not yet been demonstrated,
as the Fas ligand has not been detected in the colon, except in
subsets of lymphocytes in the lamina propria (De Maria et al,
1996). Expression of Fas protein in the colon is progressively
reduced during the transformation ofnormal epithelium to benign
neoplasms, adenocarcinomas and, ultimately, to metastases
(Leithauser et al, 1993; Moller et al, 1994). Moller and co-workers
(1994) reported that the extent of loss was related to the stage of
the disease, as only 10% of adenomas exhibited reduced Fas
expression compared with 88% of carcinomas. Total absence of
Fas was most common in non-mucinous and metastatic tumours. If
Fas is required for apoptosis of the colonic epithelial cells, it is
possible that loss ofFas activity can contribute to the reduction in
apoptotic capacity ofcolonic carcinomas.
In the present study, we have examined colonic tumours for
gross rearrangements and deletion of the Fas gene to identify a
possible mechanism by which Fas expression in the colonocytes is
reduced during malignant transformation. The gene encoding the
Fas protein has been mapped to human chromosome lOq23-24.1
(Inazawa et al, 1992; Lichter et al, 1992). Loss of this chromo-
somal arm is relatively uncommon in colorectal cancers when
detected by molecular techniques (approximately 15%; Vogelstein
et al, 1989), however a cytogenetic analysis has reported a
frequency of up to 49% (Muleris et al, 1990). The frequency of
Fas gene alterations in colonic tumours is therefore not precisely
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known and may indicate the importance of the loss ofFas protein
expression in colon tumours.
MATERIALS AND METHODS
Patients and samples
Specimens of primary colonic or rectal carcinomas with matched,
macroscopically uninvolved mucosa were obtained with informed
consent from 88 patients undergoing surgical colonic resections.
Patients had not undergone chemotherapy or radiation treatment
before the surgery. Colon specimens were snap frozen in liquid
nitrogen immediately after surgery and stored at -80°C until
analysed. Blood (10 ml) was collectedfrom 30 cancerpatients after
surgery and 109blooddonors, as asourceofcontrolgenomic DNA.
DNA extraction
High-molecular-weight DNA wasisolatedfromhomogenizedtissue
specimens or peripheral blood mononuclear cells (PBMNCs) by
incubating cells in STE buffer (0.1 M sodium chloride, 10 mm Tris
chloride pH 8.0 and 1 mm EDTA pH 8.0) containing 1% sodium
lauryl sulphate (SDS), 100 ,ug ml-1 Proteinase K and 20jg ml-
RNAase A for 16 h at 37°C. DNA was isolated from the lysates by
standard techniques (Sambrook et al, 1989).
Detection of an RFLP in the human Fas gene
A polymorphic base change (ACC to ACT) at nucleotide position
641 (relative to the translational start site) ofthe human Fas cDNA
has been reported (Fiucci and Ruberti, 1994). This base change
creates a recognition sequence for the restriction enzyme Dral. To
detect the polymorphism by polymerase chain reaction (PCR)
amplification, a genomic fragment of Fas, spanning the poly-
morphism and a 1.1-kb intron beginning 10 bp downstream ofthe
polymorphism, was amplified from genomic DNA using primers
1 and 2 (Table 1). The product was purified by spin extraction
through Wizard columns (Promega, Madison, USA), cloned into a
pGEM-T vector (Promega) and partly sequenced. Primer 3 was
then designed from the intronic sequence (Table 1) and used
with primer 1 to amplify a 115-bp product containing the poly-
morphism, which was used in the final analysis.
The 115-bp DNA sequence was amplified from genomic DNA
(100 ng) by an initial denaturation of 5 min at 94°C, 35 cycles of
denaturation for 1 min at 94°C, 1 min of annealing at 53°C and
1 min ofelongation at 72°C; followed by a final elongation step of
5 min at 72°C. All PCR reactions contained 1 unit of Taq poly-
merase (Promega) in themanufacturer's buffer, 100 ng ofprimers 1
and 3 (Table 1), 0.8 mm dNTPs, 1 x Taq polymerase buffer and 1.5
mM magnesium chloride in a final volume of50gl. PCR products
were digested directly with 20 units of DraI (New England
BioLabs, Beverly, USA) in themanufacturer's bufferfor 16-20 hat
37°C. Digested PCR products from normal and tumour DNA were
resolved by electrophoresis through 15% non-denaturing polyacry-
lamide gels in 1 x TBE buffer (89 mM Tris chloride pH 8.0, 89 mM
borate and 2 mm EDTA pH 8.0) at 150 V. Gels were stained with
ethidium bromide and photographed. Complete digestion of PCR
products was confirmed by the inclusion ofa single-base mismatch
in Primer 3 at nucleotide position 13 (G to T) to create a control
cutting site for Dral. Undigested or partly digested products were
then visible as an extra band of 115 bp above the digested bands.
Detection of allelic losses in tumours
DNA, from normal mucosa or blood, containing the DraI poly-
morphism in one allele (heterozygotes) was termed informative.
Digested PCRproducts ofnormal and tumourDNA from informa-
tive patients were run in adjacent gel lanes and compared for
allelic loss. Samples with apparent loss of heterozygosity (LOH)
were analysed by three independent amplifications. To confirm
LOH, photographs ofgels were scanned by a Bio-Rad model GS-
670 imaging densitometer and the volumes ofthe non-cutting and
cutting allele were measured using Molecular Analyst software
(Bio-Rad, Hercules, USA). Aratio ofthenon-cutting tothecutting
allele volumes was calculated as aquantitative measure ofLOH in
tumour samples.
To verify the sensitivity of the assay for detection of LOH,
peripheral blood lymphocytes from a heterozygote and homozy-
gote blood donor were mixed in various proportions to simulate
LOH of 0, 10, 25, 50, 75, 90 and 100%. DNA isolated from the
cell mixtures was used as a template for the amplification of the
DraI polymorphism and LOH in each sample was quantitated by
laserdensitometry.
Detection of rearrangements of Fas
DNA (10 ,ug) extracted from 64 tumours was digested with
60 units of the TaqI restriction enzyme (New England BioLabs)
for 3 h at65°C. Digested samples werefractionated on 1% agarose
gels and blotted onto GeneScreen Plus nylon membranes (DuPont,
Boston, USA) underalkaline conditions (Koetsieretal, 1993). The
Fas gene was detectedby hybridization ofmembranes with a full-
length cDNA probe, labelled with [32P]dCTP or [32P]dATP by
random priming (Gigaprime Kit, Bresatec, Adelaide, Australia).
The probe was cut out from the pBSAPO-14.2 plasmid (kindly
provided by Dr P Krammer) with NotI (New England BioLabs).
Membranes were hybridized in 50% deionized formamide, 1 M
sodium chloride, 10% dextran sulphate, 1% SDS and 500 gg ml-'
denatured herring sperm DNA for 16-20 h at 42°C. Membranes
were washed to the appropriate stringency and visualized by expo-
sure to Hyperfilm (Amersham, Buckinghamshire, UK) at -80°C.
Northern blot analysis of Fas mRNA
Frozen colon specimens, from patients who were informative for
the LOH assay, were pulverized under liquid nitrogen with a
mortar and pestle. The ground tissues were suspended in a lysis
buffer containing 4M guanidine thiocyanate and RNA was
isolated using the phenol-chloroform-isopropanol method
(Chomczynski and Sacchi, 1987). RNA (10jg) was electro-
phoresed through 1% agarose gels containing 17% formaldehyde.
RNA was blotted onto GeneScreen Plus nylon membranes
Table 1 Primers used for the detection of LOH by PCR
Primer Sequence Location
1 5'-TACAGAAAACATGCAGAAAGC Exon 7
2 5'-TCAGATAAATTTATTGCCACTG Exon 8
3a 5'-CTATTTTTCTTTTAAAGGAAAGC Intron 7
aPrimer 3 contains a mismatch (in bold) to create a control cutting site for
Dral.
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Figure 2 Sensitivity of the assay for detection of LOH. PCR products,
obtained by mixing PBMNCs of a normal homozygote and heterozygote in
the indicated proportions, were digested with Dral to simulate contamination
of tumours with normal cells. Densitometric values of the ratios between the
uppermost two bands in each track are charted below the figure
Figure 1 Detection of the Dral polymorphism in the Fas gene by PCR and
restriction enzyme digestion. (A) Banding patterns seen in three normal
individuals after digestion of a 115-bp PCR product with Dral. M, pUC18
digested with Hpall; 1, undigested PCR product; 2, Dral- homozygote; 3,
heterozygote; 4, Dral+ homozygote. Unconsumed primer is visible in some
samples. (B) Loss of heterozygosity in colon tumours of three representative
patients (AD, CE, SP). 1, Undigested PCR product; N, normal colonic
mucosa; T, colonic tumour. Patients AD and SP show loss of the non-cutting
allele and patient CE shows loss of the cutting allele
(DuPont) in 10 x standard saline citrate (SSC) buffer. Northern
blots were hybridized with the same Fas cDNA probe used for the
Southern analyses, under the same conditions.
RESULTS
PCR assay for detection of the Dra I polymorphism in
Fas
A DraI polymorphism, previously reported in the human Fas gene
(Fiucci and Ruberti, 1994), was used as a restriction fragment-
length polymorphism (RFLP) for the detection of allelic losses in
colonic tumours. Preliminary attempts to detect the polymor-
phism, by Southern analysis ofgenomic DNA digested with DraI,
were unsuccessful as no variations in hybridization patterns were
observed in a small normal population (data not shown). A PCR-
based assay was therefore designed to amplify a smaller region of
Fas surrounding the polymorphic site. PCR products (115 bp)
amplified from normal genomic DNA and digested with DraI
revealed either a non-cutting allele of 101 bp or cutting alleles of
61 and 40 bp (Figure IA).
A Dral site in the Fas gene was detected in 64 of 218 chromo-
somes analysed from a normal population, giving an allele
frequency for the polymorphism of 29%. Forty-six per cent of the
Table 2 Histology of informative colon tumours analysed for LOH
Tumour differentiation Informative cases Number with LOH
Villous adenoma 2 0
Well 3 0
Moderate 26 3
Moderate/poor 4 2
Unclassified 3 1
Total 38 6
Table 3 Densitometric analysis of samples with LOH
Ratio of cutting to alleles
Patient Normal mucosa Tumour LOH (%)
AD 2.3 0.6 73
CE 2.4 4.0 67
SP 1.8 0.6 67
RF 2.3 3.1 35
EC 2.9 4.9 69
MK 1.8 1.0 47
normal population were heterozygotes and therefore informative
for LOH detection. Quantitative ratios ofthe cutting to non-cutting
alleles in normal heterozygotes, calculated densitometrically from
the intensity of the DNA bands, varied depending on the gel
staining and photography conditions. However, these ratios were
consistent within a single gel, so normal and tumour DNA digests
were always analysed on the same photograph. The ratio calcu-
lated for normal heterozygotes did not vary with the number of
PCR amplification cycles or the amount of template DNA used
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Figure 3 Southern analysis of DNA from normal colonic mucosa (N) and
tumours from three individual patients (T), digested with Taql. Filters were
hybridized with a 2.5-kb full-length Fas cDNA probe. No alterations in the
hybridization pattern are evident in the tumour samples
Patients:
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Figure 4 Fas mRNA expression in matched normal mucosal (N) and
tumour (T) specimens. Northern analysis using a 2.5-kb full-length Fas cDNA
probe is shown in the upper panel and ethidium bromide staining of 18S
rRNA is shown in the lower panel to indicate RNA loading. Patient TM has
similar levels of Fas in both normal and tumour tissue, while the tumours
from patients BG and JP show reduction of Fas expression. Patient CE, who
had LOH of Fas, has no detectable expression in either the normal or the
tumour tissue
(data not shown). Lymphocytes isolated from the blood ofnormal
heterozygous and homozygous donors were mixed in various
proportions to test the sensitivity of the assay to detect allelic
losses in tumours containing normal, uninvolved cells. Analysis of
these samples revealed that losses of either the cutting or non-
cutting allele of Fas could be detected both visually and by
densitometry, despite the presence of up to 50% contaminating
heterozygous cells (Figure 2).
Of the 88 cancer patients involved in the study, 38 (43%) were
informative for the DraI polymorphism and exhibited a range of
tumourdifferentiation (Table 2). Six ofthe 38 informative tumours
(16%) exhibited partial allelic loss at the Fas locus (Figure lB),
which. was confirmed by densitometry (Table 3). Three patients
had deletions ofthe cutting allele; while thiee lost the non-cutting
allele. Because ofthe small number ofpatients with allelic loss, no
relationship between LOH and tumour stage was apparent.
Interestingly, one patient (EC) with LOH in a moderate to poorly
differentiated carcinoma had no loss in a benign colonic adenoma
removed with the tumour.
Rearrangements of Fas
Normal DNA digested with the TaqI restriction enzyme produced
three bands when hybridized with a Fas cDNA probe, one of
10 kb, one of4.2 kb and one of 1.1 kb (Figure 3). No alterations in
this banding pattern were observed in 64 tumour DNA samples
analysed. There were no apparent allelic amplifications or dele-
tions in any tumour samples, including five ofthe six patients with
LOH analysed by the PCR assay. There was not sufficient DNA
available from the remaining patient with LOH for Southern
analysis to be performed.
Expression of Fas mRNA in colon tumours
Fifteen informative colon tumours were analysed for Fas expres-
sion, 11 of which had matched normal mucosal RNA samples
(Figure 4). All except one sample of normal mucosa examined
expressed the 2.7- and 1.9-kb Fas mRNA bands previously
reported by Northern analysis (Itoh et al, 1991). Five of 15
tumours analysed expressed Fas at levels similar to that in normal
mucosa, however 10 of 15 tumours had reduced or absent Fas
expression. There was no evidence of any abnormally sized
transcripts in any ofthe tumour samples analysed.
Four of the tumour samples with LOH had sufficient tissue for
RNA extraction and analysis. Of the four patients, only one
tumour sample (MK) expressed Fas mRNA. The remaining three
tumours did not express any detectable Fas mRNA compared with
other samples analysed concurrently. Patient CE had no Fas
expression in either the tumour or the normal mucosal specimens
analysed. However, a low level of Fas mRNA expression was
detected in the tumour RNA after prolonged film exposure.
DISCUSSION
Apoptosis induced by the Fas antigen is vital for the programmed
deletion of immune cell populations and foreign cells. Despite its
widespread expression in epithelial tissues, the biological impor-
tance of Fas outside the immune system is not fully understood.
Reports ofabnormalities in Fas protein expression and function in
colon tumours and cell lines are now prevalent in the literature and
appear to be associated with a failure of apoptotic capacity of the
cells. In the present study, we have verified that Fas mRNA is
expressed constitutively in normal colonic mucosa, but Fas gene
transcription was reduced in the majority of tumours analysed.
Losses or rearrangements ofchromosomes are common in tumour
cells (Popescu, 1994) and, when accompanied by an inactivating
point mutation in the remaining allele, can abrogate the expression
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of tumour-suppressor genes. We found Fas gene rearrangements
and allelic losses to be rare events in colon cancer, suggesting that
other mechanisms are responsible for reduced Fas expression in
these tumours.
PCR-based restriction analysis was used to determine the
frequency of Fas allelic losses in colon cancer. A single base
changepolymorphism at nucleotideposition 836 ofthe Fas cDNA
has been reported by Fiucci and Ruberti (1994) with an allele
frequency of 33%. The substitution ofdeoxythymidine fordeoxy-
cytidine at this location has no functional significance for the Fas
protein, but a recognition site for the Dral enzyme is created. The
polymorphism may therefore be used to detect allelic losses ofthe
Fas gene in tumours ofheterozygotes. Because of its sensitivity,
PCR analysis is advantageous for the screening oflarge numbers
of samples, especially for very small pieces of tissue. A common
criticism ofPCR-based assays for detection ofLOH is that forma-
tion of heteroduplexes can cause false LOH results, because
heteroduplexes are often cutbyrestriction enzymes less efficiently
than are homoduplexes. In the present study, no changes in
enzyme cutting were observed, even under amplification condi-
tions that favour heteroduplex formation, including high numbers
of PCR cycles and excess template DNA. The sensitivity of the
assay was sufficient to detect LOH with up to 75% contaminating
normal cells by densitometry, however microdissection of malig-
nant cells from tumours may allow easier visual detection ofLOH.
This assay may be useful forthe detection ofLOH at the Fas locus
in other tumours with abnormal levels ofFas expression.
The allele frequency of the Dral polymorphism determined in
this study was similar to thatpreviously determinedby denaturing
gradient gel electrophoresis of Fas cDNA transcripts (Fiucci and
Ruberti, 1994). Loss ofheterozygosity was detected at this poly-
morphic locus in approximately 16% of colonic tumours. This
frequency of deletion is similar to thatreported by Vogelstein and
co-workers (1989) for loss of chromosome 10q in colon tumours,
suggesting that the LOH of Fas detected in the present study
reflects the loss of the entire chromosomal arm. Despite this low
frequency ofallelicloss, Fas genetranscription was reduced in the
majority of the informative colon tumours and could not be
detected in three tumours analysed with LOH. This suggests that
Fas deletion is not the only mechanism for loss of Fas gene
expression. In the tumours ofpatients with LOH, disruption ofthe
remaining wild-type Fas allele by a point mutation or epigenetic
mechanisms may explain thecomplete loss ofFasexpression.
Analysis ofdeletion of a geneusing asingle locus may underes-
timate the true rate of gene disruption, which can involve discrete
segments of the gene. Small deletions in the Fas gene have been
characterized in autoimmune disorders and lymphomas (Rieux-
Laucat et al, 1995; Cascino et al, 1996; Drappa et al, 1996). These
deletions remove the signal transduction or 'death' domain of the
protein, which is responsible for its cytolytic activity. To deter-
mine whether these deletions also occur in colon cancer, we exam-
ined Southern blots of tumour DNA samples for altered
hybridization patterns. Gross rearrangement of the Fas gene was
not detected in any of the colonic tumours analysed in this study,
suggesting that mechanical disruption or deletion of Fas is not
responsible for the reduced Fas expression in colon tumours.
Another study, which examined Fas rearrangements by Southern
analysis in non-Hodgkin's lymphomas, also reported a low
frequency of less than 1%, despite reports of abnormal levels of
Fas protein expression in these lymphomas (Xerri et al, 1995).
Surprisingly, no Fas gene defects ordeletions were observed in the
four tumours that had exhibited LOH in the PCR analysis. This
may be explained by the possibility that theDraI site was lostby a
small deletion or a point mutation in the enzyme's recognition
sequence. Alternatively, the presence of contaminating normal
cells in the tumour samples may prevent the detection ofchanges
in gene dosage by Southern analysis.
The importance ofFas signalling in the development oftumours
is not yet known. There have been no reports of spontaneous
tumour development in mice with germline mutation ordisruption
ofthe Fas gene. However, benign expansion oflymphocyte popu-
lations and splenomegaly occur in both mice and humans with
defective Fas genes (Wu et al, 1994; Rieux-Laucat et al, 1995),
suggesting that Fas signalling can control the growth ofcell popu-
lations. When lpr mice, which express little Fas protein as a result
of a retroviral insertion in thefas gene, are crossed with mice that
overexpress the oncogene c-myc, tumour formation occurs at a
greater rate than in the c-myc-expressing mice alone (Zornig et al,
1995). Fas deficiency also increases the incidence of B-cell
lymphoma in T-cell-deficient mice to 70%, compared with 10% in
T-cell-deficient mice with intact Fas protein (Peng et al, 1996).
These findings indicate that Fas deficiency has a permissive effect
on existing promalignant defects.
During the progression of colon cancer, the ability of colonic
epithelial cells to undergo apoptosis in response to mutagenic
challenge is compromised. The p53 protein is generally believed
to be responsible for induction of apoptosis in response to DNA
damage, however loss of p53 is a comparatively late event in
colorectal tumorigenesis (Fearon and Vogelstein, 1990). The
molecular targets of p53 that carry out the apoptotic signal are
unknown, however p53 can bind to the promoter of the Fas gene
and induce its expression (Owen-Schaub et al, 1995). If Fas is a
downstream effector of p53, its loss could directly influence cell
death in colonic tumours. However, the role of Fas signalling in
the colon and the importance of its loss in colon cancer are still
largely unknown.
Fas protein is expressed in variable levels on the surface of
several colon cancer cell lines. In some cell lines, low expression
of Fas may be up-regulated by the cytokines TNF-a or interferon
gamma (IFN-y) to levels similar to that of activated T cells
(Yonehara et al, 1989; Itoh et al, 1991; Moller et al, 1994). Cell
lines expressing Fas protein show considerable disparity in sensi-
tivity to agonistic antibodies against Fas. HT29 cells are relatively
insensitive, unless preincubated with interferon gamma or protein
synthesis inhibitors (Yonehara et al, 1989; Abreu-Martin et al,
1995), while growth of KM12C cells is inhibited by the anti-Fas
antibody (Owen-Schaub et al, 1993, 1994). Metastatic variants of
KM12C cells are more resistant to the effects of the antibody,
despite a similar level of Fas expression (Owen-Schaub et al,
1994). SW620 cells are resistant to Fas ligation, but also express
Fas ligand at levels capable of killing T cells, thus avoiding
immune deletion (O'Connell et al, 1996). Taken together, these
findings suggest that colon tumours may actively avoid immune
surveillance and increase their own survival by down-regulating
Fas expression or function.
The lack of detectable deletions or other rearrangements in the
Fas gene in colonic tumours suggests that the gene may be tran-
scriptionally silenced during colon cancer progression. There are
recognition sequences in the Fas promoter for a number of tran-
scriptional proteins including p53, c-myb and NF-KB (Behrmann
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et al, 1994; Cheng et al, 1995); the loss of any of which may
prevent Fas expression. The promoterregion ofFas is GC rich and
contains a number of CpG dinucleotides. De novo methylation of
CpG islands often occurs in tumours and has been associated with
epigenetic silencing oftumour-suppressor genes. Future studies in
this laboratory will examine the patterns of CpG methylation
in the Fas gene promoter in colonic carcinomas, as a possible
mechanism by which Fas gene transcription is reduced.
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